Assenagon Asset Management S.A. Buys 108,838 Shares of Cencora, Inc. (NYSE:COR)

Assenagon Asset Management S.A. boosted its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 462.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 132,364 shares of the company's stock after acquiring an additional 108,838 shares during the period. Assenagon Asset Management S.A. owned 0.07% of Cencora worth $29,792,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Financial Advocates Investment Management increased its holdings in Cencora by 4.7% in the second quarter. Financial Advocates Investment Management now owns 978 shares of the company's stock valued at $220,000 after buying an additional 44 shares in the last quarter. Checchi Capital Advisers LLC increased its holdings in shares of Cencora by 2.2% during the 2nd quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company's stock worth $499,000 after buying an additional 48 shares during the last quarter. Valeo Financial Advisors LLC raised its position in Cencora by 3.4% in the second quarter. Valeo Financial Advisors LLC now owns 1,566 shares of the company's stock valued at $353,000 after purchasing an additional 51 shares during the period. Impact Partnership Wealth LLC grew its holdings in shares of Cencora by 2.6% during the 3rd quarter. Impact Partnership Wealth LLC now owns 2,042 shares of the company's stock worth $460,000 after purchasing an additional 51 shares during the period. Finally, Evergreen Capital Management LLC boosted its stake in Cencora by 4.7% during the second quarter. Evergreen Capital Management LLC now owns 1,147 shares of the company's stock worth $258,000 after buying an additional 52 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Cencora

In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business's stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the sale, the insider now directly owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business's stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the sale, the insider now owns 19,980,000 shares in the company, valued at $4,806,388,800. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares in the company, valued at $67,223,750.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,461,153 shares of company stock worth $1,073,075,720 in the last 90 days. 15.80% of the stock is currently owned by company insiders.

Cencora Stock Down 0.3 %

NYSE:COR traded down $0.69 on Friday, reaching $234.47. The stock had a trading volume of 1,009,552 shares, compared to its average volume of 1,411,099. The stock has a market cap of $46.77 billion, a P/E ratio of 25.65, a price-to-earnings-growth ratio of 1.40 and a beta of 0.44. Cencora, Inc. has a 12-month low of $182.75 and a 12-month high of $247.66. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. The company has a 50-day moving average of $232.15 and a 200 day moving average of $230.81.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, beating the consensus estimate of $3.18 by $0.16. The company had revenue of $74.20 billion during the quarter, compared to analysts' expectations of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. During the same period in the prior year, the business posted $2.92 EPS. The business's revenue was up 10.8% on a year-over-year basis. On average, research analysts predict that Cencora, Inc. will post 13.63 earnings per share for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were given a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend was Friday, August 9th. Cencora's payout ratio is 22.32%.

Wall Street Analyst Weigh In

Several research analysts have recently commented on COR shares. Evercore ISI lowered their price objective on shares of Cencora from $270.00 to $250.00 and set an "outperform" rating for the company in a research note on Tuesday, October 8th. Bank of America reissued a "neutral" rating and set a $245.00 price objective (down previously from $275.00) on shares of Cencora in a report on Wednesday, September 18th. StockNews.com cut shares of Cencora from a "strong-buy" rating to a "buy" rating in a report on Friday, September 20th. JPMorgan Chase & Co. raised their target price on shares of Cencora from $280.00 to $287.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 21st. Finally, Wells Fargo & Company upped their target price on shares of Cencora from $236.00 to $249.00 and gave the company an "equal weight" rating in a report on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $259.44.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.